leisure time -WSS

leisure time

author：entertainment 2025-10-01 05:40:12 - browse：498

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： FDA clears AI tool for detecting skin cancer

knowledge

WSS

FDA clears AI tool for detecting skin cancer

The tragedy of Johnson & Johnson’s Covid vaccine

ADA: All diabetes patients should be screened for liver condition

Independent physicians launch a new lobbying group

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Here's how to stay safe from wildfire smoke amid reduced air quality

explore

leisure time

entertainment

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

As demand for Covid shots wanes, Moderna seeks its next success

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

DIEP, the 'gold standard' of breast reconstruction, is under threat

Tuskegee Airman Raymond Cassagnol dies at 102

Virginia high school admissions case could be legal follow

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Activists slam private health insurers over coverage restrictions

The surgeon had a dilemma only a Nazi medical text could resolve

focus

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Eating disorder hotline's move to chatbot carried cost for volunteers

Supreme Court rules employers must be more accommodating of religious observance

Eating disorder hotline's move to chatbot carried cost for volunteers

My yearlong odyssey to get my son’s ADHD medication covered

The strange history of BMI, the body mass index

hotspot

knowledge

focus

entertainment